A single-arm double-blind placebo-controlled cross-over trial of Aprepitant for the treatment of cough in lung cancer: CALC trial

Christie Hospital NHS Foundation Trust (UK)0 个研究点目标入组 20 人开始时间: 2013年3月26日最近更新: 2020年10月5日

适应症

试验速览

•1. Patients willing and able to give consent for participation in the trial
•2. Male or female aged 18 years or above
•3. WHO PS 02
•4. Diagnosed with lung cancer
•5. Able and willing to participate in and comply with the trial schedule
•6. Persistent cough >= 4 weeks
•7. Not on anticancer therapy
•8. No anticancer therapy planned to commence for the duration of the trial participation

•1. Received anticancer therapy within 4 weeks of trial entry
•2. Receiving Aprepitant therapy
•3. Presence of a RTI within last 4 weeks
•4. Previous adverse event to Aprepitant
•5. Presence of constipation grade 2 or above (CTCAE v4)
•6. Scheduled elective surgery or other procedures requiring sedation or general anaesthesia during trial period
•7. Potentially fertile women of childbearing age
•8. Currently participating in another research trial involving an investigational product
•9. Any other significant disease or disorder which, in the opinion of the investigator, may either put the patient at risk because of participation in the trial or affect the patient?s ability to participate in the trial

发起方

Christie Hospital NHS Foundation Trust (UK)